North China Pharmaceutical Co., Ltd. (600812.SH) announced its wholly-owned subsidiary, Huasheng Company, recently obtained the Certification of Suitability to European Pharmacopoeia (CEP) for Polymyxin B Sulfate active pharmaceutical ingredient (API) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).
Polymyxin B Sulfate treats acute infections caused by Pseudomonas aeruginosa-susceptible strains, serving as the primary medication for urinary tract, meningeal, and bloodstream infections induced by this pathogen. This therapeutic agent is also indicated for severe infections stemming from susceptible strains of Haemophilus influenzae (particularly meningeal infections), Escherichia coli (especially urinary tract infections), Enterobacter aerogenes (notably bacteremia), and Klebsiella pneumoniae (specifically bacteremia) when lower-toxicity alternatives prove ineffective or contraindicated.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。